Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease

Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial

A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials

Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial

Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial

A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials

Pers/media

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes

First-in-class treatment delivers major advance for incurable kidney disease

First-in-Class Treatment Brings Major Breakthrough for Incurable Kidney Disease

First-in-class treatment delivers major advance for incurable kidney disease

Diabetes drug can slow kidney function decline, study finds

La dapagliflozina no reduce los riesgos en los pacientes hospitalizados con COVID-19